With technological innovation as its wings, Saikesaisi is sprinting towards IPO and setting sail for the high-end medical blue ocean
2024-08-07
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
With the dual improvement of national living standards and health awareness, my country is entering a new era with a surge in demand for high-quality medical services. The accelerated arrival of an aging society and the continuous expansion of the chronic disease patient population have drawn a broad growth blueprint for the high-end medical device market. As the cornerstone of health and wellness, the development of the medical equipment industry is directly related to the life and health of the people and the transformation and upgrading of the entire industry. Against this background, Seikesaisi Biotechnology Co., Ltd. ("Seikesaisi") is sprinting for an IPO with technological innovation as its wings, vowing to write a new glorious chapter in the field of implantable biomaterials.
Innovation-driven, filling market gaps
Seikesaisi has been deeply engaged in the field of implantable biomaterials for many years. With its profound scientific research background and unremitting pursuit of innovation, it has built a complete scientific research system and industrial layout. The company's core products, such as composite microporous polysaccharide hemostatic powder and carboxy chitosan surgical anti-adhesion fluid, not only occupy a leading position in the domestic market, but also have won wide recognition for their excellent performance and safety. What is even more valuable is that Seikesaisi has successfully developed domestic first-of-its-kind products in multiple segments, filling market gaps, and its technical strength has reached the international advanced level, demonstrating strong independent innovation capabilities and industry leadership.
Technology-led, future medical planning
The field of implantable biomaterials, as a frontier of medical technology, is known for its high degree of comprehensiveness and technical difficulty. Seikesais knows that only by continuous innovation can we lead the future. The company focuses on key areas such as hemostasis and anti-adhesion, tissue sealing and protection, interventional embolization and tissue engineering. Through continuous technology research and development and product iteration, it not only meets the urgent needs of the current market, but also lays a solid foundation for the development of future medical technology. The company's strong technical reserves and ability to respond quickly to market changes enable it to always maintain a leading position in the fierce market competition.
Talents gather to seize the high ground of scientific research
Talent is the first resource for enterprise development. Since its establishment, Seikesais has always attached great importance to the construction and training of the R&D team. At present, the company has an elite R&D team composed of high-level talents such as doctors and masters. They have accumulated rich technical experience in the field of implantable biomaterials and have strong independent R&D capabilities. At the same time, the company also actively cooperates with well-known scientific research institutions at home and abroad, continuously introduces advanced technologies and concepts, and injects strong impetus into the company's continuous innovation. The high recognition of the company's R&D team by the Jinan Municipal People's Government and the Jinan High-tech Industrial Development Zone Management Committee further demonstrates Seikesais' outstanding achievements in talent development.
Looking to the future, drawing a blueprint for health
Standing at a new historical starting point, Seikesaisi is sprinting towards the IPO with unprecedented determination and courage. This is not only an affirmation of the company's past achievements, but also a firm confidence in future development. Seikesaisi will continue to uphold the corporate spirit of "innovation, excellence, and win-win", guided by market demand and driven by technological innovation, and continue to launch more implantable biomaterial products with international competitiveness, contributing to the modernization of my country's medical equipment industry. At the same time, the company will also actively fulfill its social responsibilities, committed to improving the health level of the whole people, and contribute to building a healthy China.
